- Home
- CUE vs HSPO Comparison
CUE vs HSPO Comparison
Compare CUE & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- HSPO
- Stock Information
- Founded
- CUE 2014
- HSPO 2014
- Country
- CUE United States
- HSPO United States
- Employees
- CUE N/A
- HSPO N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- HSPO Blank Checks
- Sector
- CUE Health Care
- HSPO Finance
- Exchange
- CUE Nasdaq
- HSPO Nasdaq
- Market Cap
- CUE 77.3M
- HSPO 90.8M
- IPO Year
- CUE 2018
- HSPO 2022
- Fundamental
- Price
- CUE $1.31
- HSPO $11.42
- Analyst Decision
- CUE Strong Buy
- HSPO
- Analyst Count
- CUE 5
- HSPO 0
- Target Price
- CUE $5.00
- HSPO N/A
- AVG Volume (30 Days)
- CUE 406.9K
- HSPO 2.8K
- Earning Date
- CUE 03-10-2025
- HSPO 01-01-0001
- Dividend Yield
- CUE N/A
- HSPO N/A
- EPS Growth
- CUE N/A
- HSPO 2.63
- EPS
- CUE N/A
- HSPO 0.28
- Revenue
- CUE $9,532,000.00
- HSPO N/A
- Revenue This Year
- CUE $73.11
- HSPO N/A
- Revenue Next Year
- CUE $11.02
- HSPO N/A
- P/E Ratio
- CUE N/A
- HSPO $40.54
- Revenue Growth
- CUE 149.53
- HSPO N/A
- 52 Week Low
- CUE $0.45
- HSPO $11.42
- 52 Week High
- CUE $2.93
- HSPO $11.90
- Technical
- Relative Strength Index (RSI)
- CUE 52.47
- HSPO 49.79
- Support Level
- CUE $1.21
- HSPO $11.33
- Resistance Level
- CUE $1.75
- HSPO $11.72
- Average True Range (ATR)
- CUE 0.18
- HSPO 0.09
- MACD
- CUE 0.00
- HSPO -0.01
- Stochastic Oscillator
- CUE 45.00
- HSPO 15.79
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.